Abstract
Lung cancer is one of the most common and lethal types of cancer worldwide, needing novel therapeutic approaches to enhance patient outcomes. Nanotechnology has emerged as a viable approach to cancer treatment, providing precise drug administration and increased therapeutic efficacy. In this research, we have developed pH-responsive nanodispersion for targeted drug delivery to non-small cell lung cancer. Bevacizumab and calcium phosphate nanoparticle-loaded nanodispersion (BZ-CaP-NDs) were synthesized using a high-pressure homogenization technique. BZ-CaP-NDs are optimized by means of particle size and encapsulation efficiency, and further subjected to the analysis of zeta potential, FTIR, molecular docking, in-vitro release, hemolytic potential assay, and erythrocyte aggregation assay. The analysis for particle size and zeta potential of the optimized BZ-CaP-NDs was found to be 182 ± 1.1 nm and −25.6 mV (Trial 4), respectively. In-vitro drug release showed the efficiency of BZ-CaP-NDs to release BZ at acidic conditions (85.65 ± 1.2%, 72.11 ± 0.98% was released in pH 6.5 and pH 7.4 at 48 h, respectively). Molecular docking studies resulted efficient binding of bevacizumab to VEGF-A protein. The results of the erythrocyte aggregation and hemolytic potential assays indicated that BZ-CaP-NDs were not hazardous, which indicates that, using them for intravenous drug delivery is safe. Thus, the developed BZ-CaP-NDs would be a promising solution for non-small cell lung cancer treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.